Elicio Therapeutics, Inc. (ELTX) AI-Powered Stock Analysis
See how Elicio Therapeutics, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
ELTX●NASDAQ
HealthcareBiotechnology
$3.85
$0.86(18.26%)
U.S. Market opens in 0h 59m
Advertisement
Elicio Therapeutics, Inc. (ELTX)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerElicio Therapeutics, Inc. (ELTX) Stock Overall Grade
Elicio Therapeutics, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Elicio Therapeutics, Inc.'s overall stock rating.
Forecast
BScore
65/100Financial Growth
CScore
40/100Fundamental Growth
B+Score
77/100Key Ratios
C+Score
55/100Sector Comparison
C+Score
50/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
99/100Analyst Consensus
B+Score
75/100Elicio Therapeutics, Inc. (ELTX) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 65/100 (B), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (77/100, B+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (50/100, C+) indicate weak positioning. Compared to broader benchmarks like the S&P 500 (99/100, A+), it shows competitive strength. Analyst Consensus (75/100,B+) suggests Low divergence in outlook.Component Analysis Explained
Understand the key factors behind each Elicio Therapeutics, Inc. stock grade, including financials, comparisons, and forecasts.